Cytomegalovirus (CMV) is one of the major viral infections after organ transplantation, with considerable clinical illness, allograft loss, and increased mortality [1] . CMV has evolved multiple strategies to counteract recognition by the host immune system, enabling the virus to establish lifelong latency [2] . CMV encodes numerous proteins and microRNAs targeting HLA expression, as well as ligands of the activating natural killer (NK)-cell receptor NKG2D, which impair T-or NK-cell responses. At the same time, CMV proteins like pUL18 (an HLA class I homolog) promote inhibitory NK-cell signaling [3] . Moreover, CMV is able to modulate cell-surface expression of the nonclassical HLA class I molecule HLA-E [4, 5] .
HLA-E has been demonstrated to exhibit regulatory functions in innate and adaptive immune responses by presenting HLA-and pathogen-derived peptides [6] . It has the capacity to bind peptide sequences of various viruses, such as HIV, HBV, HCV and CMV [7] . Depending on the presented peptide and the corresponding receptor, HLA-E elicits opposing responses from effector cells. Via the inhibitory CD94/ NKG2A receptor presented on T and NK cells, HLA-E dampens immune responses. Conversely, interactions with activating CD94/NKG2C or T-cell receptor can stimulate CD8 T and NK cells [6] .
Remarkably, by encoding for viral pUL40 glycoprotein, CMV has evolved a decoy for HLA-E that perfectly mimics HLA class I signal peptides and can bind HLA-E in a manner independent of the transporter TAP [5] . It is of importance that the pUL40-derived peptide and HLA-E complex displays a higher affinity to the inhibitory CD94/NKG2A receptor, thereby promoting inhibition of NK cell-mediated lysis [8] . This mechanism indicates that CMV exploits HLA-E and highlights the relevance of HLA-E for CMV infection [4, 8] .
In contrast to classical HLA class I molecules, HLA-E exhibits only few allelic variations. The most prevalent variants among white individuals are HLA-E*01:01 (HLA-E107R) and HLA-E*01:03 (HLA-E107G), which occur with similar frequencies [9] . The protein sequences of these 2 alleles differ only at amino acid position 107 (arginine vs glycine). However, HLA-E*01:03 exhibits higher peptide affinity and thermo-stability resulting in significantly higher cell-surface expression and stronger potential to inhibit NK-cell activity compared to HLA-E*01:01 [9] . Considering the functional differences between HLA-E allelic variants, we hypothesized that these allelic variants affect the clinical occurrence of CMV infection or disease after kidney transplantation and might serve as predictive parameter to identify patients at high-risk of CMV infection.
MATERIALS AND METHODS
In total, 192 recipients of living-donor kidney transplants and 192 corresponding donors from the living-donor kidney program at University Hospital Essen (Essen, Germany) were enrolled. Transplantations were performed from 2003 to 2014. Supplementary Table 1 shows detailed cohort characteristics. Occurrence of CMV infection was monitored for the first year after transplantation. The following data were collected: demographic and transplant-related characteristics of recipients and donors, incidence of first episode of CMV infection or disease, and occurrence of biopsy-proven rejection within 12 months after transplantation.
Standard induction immunosuppression consisted of therapy based on basiliximab and a calcineurin inhibitor in combination with steroids and an antiproliferative drug. Most (155) recipients received tacrolimus as a calcineurin inhibitor. Altogether, 180 recipients were treated with mycophenolic acid, 6 were treated with azathioprine, and 6 received no antiproliferative comedication. None of the patients received an mTOR kinase inhibitor (mTORi).
For stratifying the risk of developing CMV infection or disease, pretransplantation donor and recipient anti-CMV immunoglobulin G (IgG) antibody status was evaluated using a chemiluminescence-based assay (LiaisonXL, DiaSorin, Saluggia, Italy). An anti-CMV IgG titer of ≥14 U/mL indicated seropositivity. High-risk recipients were defined as being CMV seronegative (R−) and receiving an allograft from CMVseropositive donors (D+). The intermediate-risk group comprised all CMV-seropositive recipients independent of donor CMV serologic status (D+/R+ or D−/R+), while the low-risk group included CMV-seronegative recipients receiving an allograft from CMV-seronegative donors (D−/R−). Before the end of 2011, our center-specific CMV prophylaxis regimen consisted of (val-)ganciclovir during first 100 days for high-risk CMV recipients and for patients receiving lymphocyte-depleting induction therapy. Because of emerging data suggesting that the incidence of CMV infection was lower among patients receiving prolonged antiviral prophylaxis, the duration of the prophylactic CMV regimen was changed to 200 days for the high-risk population in 2012 [10] . All other patients (ie, those with an intermediate or low risk of CMV infection) were preemptively monitored for CMV. For patients at high risk for CMV infection, screening for CMV was performed during prophylaxis only if CMV infection or disease was clinically suspected and thereafter on monthly basis. For intermediate-and low-risk patients, regular screening for CMV was recommended weekly for 3 months and, later on, monthly.
In accordance with international recommendations [11] , CMV infection was defined as detection of viral load or antigens and CMV disease as end-organ disease or CMV syndrome. Threshold values for initiation of antiviral therapy were as follows: >600 IU/mL (by PCR) for CMV DNAemia and >1/100 positive cells for CMV pp65 antigenemia. Because of severe leukopenia, the prophylactic dose of valganciclovir was reduced in 3 cases, resulting in breakthrough CMV infections. Five recipients had a breakthrough infection despite prescription of an adequate dose of valganciclovir. Twelve recipients developed delayed-onset CMV infection or disease, all but 1 of whom were HLA-E*01:03 allele carriers. CMV events were equally distributed throughout the study period. Patients with CMV disease (2 with CMV gastrointestinal disease and 1 with CMV pneumonia) were initially treated with intravenous ganciclovir and continued treatment with oral valganciclovir; asymptomatic CMV replication was treated with valganciclovir. Owing to low event rates, recipients with CMV infection or disease were combined and analyzed together.
HLA-E and NKG2C deletion genotyping were performed as previously described [12, 13] .
Informed consent was obtained from all patients, and the local ethics committee approved the study.
Baseline characteristics of donors and recipients were compared with the 2-sided Fisher exact or Wilcoxon rank sum test, as appropriate. The occurrence of CMV infection or disease was estimated by the method of Kaplan-Meier and compared using the log-rank test. Multivariate Cox proportional hazards modeling was used to assess the risk of CMV infection after transplantation. Risk factors for CMV infection were screened with unadjusted Cox models. Variables with a P value of <.10 in univariate analysis were included in the multivariable Coxregression model. Two-sided P values of ≤.05 were considered statistically significant. In total, 10% of recipients (20 of 192) exhibited at least 1 episode of clinically significant CMV infection or disease requiring antiviral treatment during the first year after transplantation. Intriguingly, we found that the incidence of CMV infection or disease was significantly higher among recipients carrying the HLA-E*01:03 allele (homozygous or heterozygous) than among noncarriers. When time course was taken into consideration, the results of Kaplan-Meier curve analysis combined with those of log-rank test ( Figure 1A ) indicated that the incidence of CMV infection or disease during the first year after kidney transplantation was significantly higher among recipients carrying the HLA-E*01:03 allele than among noncarriers (P = .0091; odds ratio [OR], 9.66; 95% CI, 1.62-102.6). Similar results were obtained when recipients at high-risk of CMV infection were assessed separately (P = .036; OR, 8.412; 95% CI, 1.29-96.8; Figure 1B ). In addition, there was also a trend toward an increased incidence of CMV infection or disease for HLA-E*01:03 positive recipients in the non-prophylactic treatment group (P = .097; OR, 36.5; 95% CI, .26-51 226.47; Figure 1C ). To elucidate whether deletion of the gene encoding the HLA-E cognate-activating CD94/NKG2C receptor contributed to impaired NK-cell responses to CMV, the incidence of NKG2C deletion in donors and recipients was investigated. About 5.7% and 30.2% of recipients and 1.7% and 37.0% of donors showed a homozygous and heterozygous NKG2C deletion, respectively. The Fisher exact test (P = .063) and Kaplan-Meier curve analysis combined with the log-rank test (P = .065; OR = 2.2; 95% CI 0.93-5.4) revealed a tentative association between NKG2C deletion and CMV infection or disease (Supplementary Figure 1A  and 1B) .
RESULTS

HLA-E allelic
Neither the donor HLA-E genotype nor the presence of an HLA-E*01:03 mismatch or NKG2C deletion status were associated with CMV infection or disease.
Univariate analysis determined that CMV high-risk status, use of lymphocyte-depleting induction therapy, and recipient HLA-E*01:03 allele carriage were risk factors for CMV infection or disease (Table 1) . Consequently, multivariate Cox regression analysis added recipient HLA-E*01:03 allele carrier status to the list of significant independent prognostic risk factors for CMV infection or disease during the first year after transplantation (P = .03; hazard ratio, 9.27; 95% CI, 1.24-69.3) along with the well-known risk factors of CMV high-risk status or use of lymphocyte-depleting induction therapy (P < .0001; hazard ratio, 9.34; 95% CI, 3.3-25.7). NKG2C gene deletion was not an independent parameter in the multivariate analysis.
DISCUSSION
The present study is the first to show that recipient HLA-E allelic variation is an independent genetic prognostic factor for CMV infection or disease during the first year after kidney transplantation, in addition to the well-known risk factors of CMV highrisk status or use of lymphocyte-depleting induction therapy.
Implementing CMV prophylaxis strategies has remarkably reduced the incidence of CMV infections among transplant recipients [1] . However, this approach does not completely Figure 1 . Association between recipient HLA-E allelic variants and occurrence of cytomegalovirus (CMV) infection or disease within 12 months after living-donor kidney transplantation. Recipients with an HLA-E*01:03 allele carrier status had a significantly increased likelihood of CMV replication overall (A) and among individuals at high risk (B) and a trend toward an increased incidence of CMV replication in the non-prophylactic treatment cohort (C). HLA-E*01:03 allele carrier status was tested for its association with CMV infection or disease, using Kaplan-Meier curves and log-rank testing.
eliminate the risk of infection. The CMV infection or disease rate of approximately 10% found in the present single-center study is within the rates described in previous studies of risk-adapted CMV prophylaxis [14] . Patients at high-risk of CMV infection have a particularly high likelihood of delayed-onset CMV infection or disease during the first 6 months after antiviral prophylaxis is discontinued. Considering the negative impact of CMV on patient and allograft survival, identification of additional predictive markers indicating which patients are especially prone to this infection is urgently needed [1] . Treatment strategies for these high-risk patients could include extended use of prophylaxis, administration of CMV immunoglobulins, or use of alternative immunosuppressive regimens. Available evidence indicates that mTORi is effective against CMV, and the results of recent studies show that administration of the mTORi everolimus reduces the risk of CMV infection [14] . In our cohort, the presence of the HLA-E*01:03 allelic variant in recipients was associated with a higher incidence of CMV infection. A growing body of evidence suggests that the immunomodulatory molecule HLA-E facilitates viral immune evasion [7] . HLA-E can bind various viral peptides, such as those derived from the CMV immune evasion protein pUL40, and this binding can lead to upregulated HLA-E expression [8] . Moreover, it has been previously documented that the UL40-HLA-E complex suppresses the activity of NKG2A-positive NK-cell clones in vitro [5] . However, recent findings indicate that HLA-E cannot only exhibit immune-tolerogenic functions but can also facilitate immune activation [6, 12] . Potential HLA-E-dependent CMV-specific immune control pathways in both the innate and adaptive immune system have been described. Driven by latent CMV infection, the NK-cell repertoire is modified toward a dominant expression of the activating NKG2C receptor, thereby priming NK-cell cytotoxicity [3] . NKG2C deficiency occurs in 4% of the healthy population [13] and was present in 1.7% of our donor cohort, whereas it was present in 5.7% of our recipients. Nevertheless, multivariate analysis showed that the NKG2C gene deletion was not an independent risk factor for CMV infection or disease in our recipient cohort. Interestingly, it has recently been shown that vaccinating rhesus macaques against simian immunodeficiency virus with rhesus CMV vectors resulted in an HLA-E-specific presentation of peptides that were recognized by CD8 + T-cells [15] . None of the published functional studies specifically examined the effect of HLA-E allelic variants, and very few clinical studies were focused on determining the effect of these allelic variants on outcomes after hematopoietic stem cell or solid organ transplantation. HLA-E * 01:03 is characterized by a stronger affinity for various peptides and a higher level of thermal stability than HLA-E * 01:01 and, thus, is associated with higher-level expression of cell-surface and soluble molecules [9] . These functional differences of the HLA-E alleles have been suggested to result in differential effects on T-and NK-cell function and, thus, could partially explain the present findings. However, because this single-center analysis is limited by its retrospective nature, its findings must be confirmed by future prospective studies.
In conclusion, the present study presents evidence indicating that assessing recipient HLA-E allelic variants may enable physicians to identify individuals within the CMV high-risk transplant population who are even more prone to CMV infections (ie, HLA-E*01:03 allele carriers) and thereby allow the future development of individual-tailored CMV approaches within this difficult-to-treat patient cohort.
